Regulatory FDA hands BeOne, Taiho approvals for blood cancers PharmaphorumBeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.HematologyRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regulatory round-up: A month of key FDA approvals for cancer drugsNext: Regenxbio’s Duchenne gene therapy clears phase 3 hurdle Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
